CVVT participated in the Asia Summit on Global Health 2022

CVVT recently participated in the Asia Summit on Global Health (ASGH), a two-day event jointly organized by the Hong Kong Special Administrative Region Government and the Hong Kong Trade Development Council on November 10 & 11, 2022. During the summit, we showcased major research and development (R&D) achievements in vaccinology.

We believe mucosal and universal vaccine will be the next generation vaccine to protect individuals from infections of current and emerging infectious diseases. Our research team introduced our latest innovations, the Dual Flu-COVID Intranasal Vaccine and the Replication Defective Intranasal Vaccine at the exhibition. The Flu-COVID bivalent vaccine is designated to fight both Flu and COVID-19 in one intranasal vaccination. It is based on a novel technology by removing a key virulent gene, NS1, from influenza viral genome for expressing RBD of SARS-CoV-2 spike protein to induce immunity to both Flu and SARS-COV-2 viruses. Clinical trials have proved Flu-COVID bivalent is highly safe and immunogenic. It is now evaluated for human use in Phase III trials.​

The Replication Defective Intranasal Vaccine is a live attenuated vaccine consisting of a live-attenuated SARS-CoV-2 virus that is capable of replicating for a single round strictly. Studies showed that it exhibited broad-spectrum protection against SARS-like viruses beyond SARS-CoV-2.​

Helmed by renowned HKU microbiology researchers and overseas collaborators, CVVT was established in 2020 under the government-funded InnoHK initiative to develop novel treatments and vaccines against emerging infectious diseases.  COVID-19 and influenza pose great threats to the public health, CVVT is committed to developing next generation vaccines to fight against resurgence of infectious disease outbreaks, and to making a positive impact on global public.

Click HERE to learn more about ASGH.

More information about CVVT’s innovations: https://www.cvvt.hk/ourtechnology